Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;124(5):925-932.
doi: 10.1038/s41416-020-01188-7. Epub 2020 Nov 30.

Prognostic impact of peripheral blood neutrophil to lymphocyte ratio in advanced-stage pulmonary large cell neuroendocrine carcinoma and its association with the immune-related tumour microenvironment

Masayuki Shirasawa  1 , Tatsuya Yoshida  2   3 , Hidehito Horinouchi  1 , Shigehisa Kitano  4 , Sayaka Arakawa  1 , Yuji Matsumoto  1 , Yuki Shinno  1 , Yusuke Okuma  1 , Yasushi Goto  1 , Shintaro Kanda  1 , Reiko Watanabe  5 , Noboru Yamamoto  1   4 , Shun-Ichi Watanabe  6 , Yuichiro Ohe  1 , Noriko Motoi  7
Affiliations

Prognostic impact of peripheral blood neutrophil to lymphocyte ratio in advanced-stage pulmonary large cell neuroendocrine carcinoma and its association with the immune-related tumour microenvironment

Masayuki Shirasawa et al. Br J Cancer. 2021 Mar.

Abstract

Background: The prognostic value of the neutrophil-to-lymphocyte ratio (NLR) with large cell neuroendocrine carcinoma (LCNEC) patients remains unclear. Thus, we performed a retrospective study to examine the relationship between the pretreatment NLR and clinical outcome in advanced LCNEC patients and the impact of the immune-related tumour microenvironment (TME).

Methods: This retrospective study included 63 advanced LCNEC patients who had received chemotherapy. We collected clinical data and investigated the TME status (CD4, CD8, CD20 and FOXP3).

Results: The overall survival of the patients with a low NLR (<5) was significantly longer than those with a high NLR (≥5) (14.9 vs. 5.2 months; p < 0.001). A multivariate analysis identified a high NLR as a predictor of a poor prognosis (HR, 3.43; 95% CI, 1.73-6.79; p < 0.001). The NLR was inversely correlated with tumoural and stromal CD8-positive tumour-infiltrating lymphocytes (tumoural: r = -0.648, p = 0.005, stromal: r = -0.490, p = 0.046).

Conclusions: A high NLR was associated with a poor prognosis in advanced LCNEC patients. Our study revealed that the NLR can reflect the TME, at least in part, suggesting that the NLR plays an important role not only as a clinical outcome predictor but also as a tumour immune status indicator.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Kaplan–Meier analysis of PFS and OS according to NLR value (n = 67).
a PFS and b OS in all patients with a low NLR (blue) vs. patients with a high NLR (red). P values were determined using the log-rank test; the number of individuals in each group and the median survival time (95% CI) are indicated.
Fig. 2
Fig. 2. Overview of pathology slides in two patients.
Representative images of pathology slides showed a high-density positive TILs tumour (upper) and a low-density positive TILs tumour (lower) in patients with LCNEC. HE-positive (a and f), CD4-positive (b and g), CD8-positive (c and h), FOXP3-positive (d and i) and CD20-positive (e and j) TILs in the tumour nest and stroma area are visible (Bar = 50 μm).
Fig. 3
Fig. 3. Relation between the NLR in preoperative blood tests and the TILs status in the TME.
Relation between the NLR value in preoperative blood tests and the density of tumoural and stromal CD8-positive (a and b), CD4-positive (c and d), CD20-positive (e and f) and FOXP3-positive (g and h) cells in the TME.
See this image and copyright information in PMC

References

    1. Travis WD. Pathology and diagnosis of neuroendocrine tumors: lung neuroendocrine. Thorac. Surg. Clin. 2014;24:257–266. - PubMed
    1. Travis, W. D., Brambilla, E., Burke, A., Marx, A., Nicholson, A. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. (IARC Press, Lyon, France, 2015). - PubMed
    1. Niho S, Kenmotsu H, Sekine I, Ishii G, Ishikawa Y, Noguchi M, et al. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study. J. Thorac. Oncol. 2013;8:980–984. - PubMed
    1. Metro G, Ricciuti B, Chiari R, Baretti M, Falcinelli L, Giannarelli D, et al. Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: implications for clinical practice. Lung Cancer (Amst., Neth.) 2016;95:82–87. - PubMed
    1. Prelaj A, Rebuzzi SE, Del Bene G, Giron Berrios JR, Emiliani A, De Filippis L, et al. Evaluation of the efficacy of cisplatin-etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNEC. ERJ Open Res. 2017;3:00128-2016. - PMC - PubMed

Publication types

MeSH terms